Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-01	SEK 0.8080	+1.00%	707,328
26-08-31	SEK 0.8000	-4.76%	680,209
26-08-28	SEK 0.8400	-0.59%	1,676,168
26-08-27	SEK 0.8450	+1.32%	887,200
26-08-26	SEK 0.8340	-1.18%	914,405

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 12:00:00 2026-09-01 EDT			5-day change	1st Jan Change
0.8080 ^SEK	+1.00%		-4.27%	-2.53%

08-20	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	164M 17.07M 14.72M 13.85M 12.62M 23.73M 1.62B 23.86M 63.73M 824M 64.09M 62.7M 2.73B	P/E 2026 *	-2.99x	P/E 2027 *	-2.13x
Enterprise Value	148M 15.4M 13.28M 12.5M 11.38M 21.41M 1.46B 21.52M 57.5M 744M 57.82M 56.57M 2.47B	EV / Sales 2026 *	4.71x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

08-20	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
08-20	Alzinova reports reduced operating loss	FW
08-20	Calendar Thursday, August 20	FW
06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW

08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
25-10-06	Alzinova gets fast track designation from US FDA	RE

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08-24	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
08-20	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
08-20	Alzinova publishes interim report for the period January - June 2026	AQ
07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ

1 day	+1.00%
1 week	-4.27%
Current month	+1.00%
1 month	-30.34%
3 months	+80.76%
6 months	+31.38%
Current year	-2.53%

1 week	0.77	0.9
1 month	0.75	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	2024-09-30
Anders Sandberg COO	Chief Operating Officer	54	2011-08-16
Erik Kullgren DFI	Director of Finance/CFO	57	2024-03-26

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	2015-08-31
Anders Waas BRD	Director/Board Member	69	2017-12-31
Carol Routledge BRD	Director/Board Member	-	2017-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+1.00%	-4.27%	-37.85%	-73.94%	16.92M
LONZA GROUP AG	+0.21%	-2.69%	+1.19%	+17.32%	49.81B
REVOLUTION MEDICINES, INC.	+2.09%	-0.71%	+452.73%	+498.77%	44.06B
IQVIA HOLDINGS INC.	-1.09%	-0.41%	+35.40%	+15.17%	42.99B
BEONE MEDICINES AG	-0.26%	-4.71%	+17.19%	+71.67%	40.88B
CELLTRION, INC.	-0.48%	-0.84%	+16.25%	+49.80%	33.11B
MEDPACE HOLDINGS, INC.	-1.81%	-5.02%	+22.65%	+113.24%	16.58B
ASCENDIS PHARMA A/S	-1.06%	+2.87%	-	-	17.27B
EUROFINS SCIENTIFIC SE	-1.35%	-3.40%	+10.13%	+26.34%	14.63B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.05%	-5.14%	+72.89%	+34.69%	13.76B
Average	-0.64%	-1.94%	+65.62%	+83.67%	27.31B
Weighted average by Cap.	-0.51%	-1.88%	+94.96%	+120.42%

	2026 *	2027 *
Net sales	31.35M 3.27M 2.82M 2.65M 2.42M 4.54M 310M 4.57M 12.2M 158M 12.27M 12M 523M	-
Net income	-4.45M -464K -400K -376K -343K -645K -44.03M -648K -1.73M -22.4M -1.74M -1.7M -74.26M	-77M -8.03M -6.92M -6.51M -5.93M -11.16M -762M -11.22M -29.97M -388M -30.14M -29.48M -1.28B
Net Debt	-16M -1.67M -1.44M -1.35M -1.23M -2.32M -158M -2.33M -6.23M -80.52M -6.26M -6.13M -267M	-19M -1.98M -1.71M -1.61M -1.46M -2.75M -188M -2.77M -7.4M -95.62M -7.44M -7.28M -317M